It is unlikely clinical activity in the RCC cohort would have been impaired if all patients had received the 120 mg daily dose of stitravatinib, given concentration-dependent modulation of plasma VEGF-A and soluble-VEGF-R2 levels was consistent with effective targeting of the VEGF-R family at both doses of study treatment [6]. This evidence concerns the gene VEGFA and renal cell carcinoma.